Plain-English translation of NCT06047379 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new oral medication called NEO212 to see if it can safely treat certain brain tumors (astrocytoma and glioblastoma) and cancers that have spread to the brain. The study is being done in phases — first to find the right dose that is safe, then to confirm safety when combined with other approved cancer medications, and finally to test how well it works.
Many patients with these types of brain tumors and metastatic brain cancers have limited treatment options and their cancers continue to grow despite current therapies. This medication is being tested to see if it offers a new, potentially more effective way to treat these serious conditions.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the medication by mouth on specific days in 28-day treatment cycles. You will have regular visits to the clinic for blood tests and imaging scans (MRI and/or CT) to monitor how you're responding and check for side effects. Depending on which phase of the study you enter, you may receive the medication alone or combined with another approved cancer medication given through an IV infusion.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States